Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now

2025-09-23 11:36:29 ET

Prime Medicine, Inc. ( PRME ) stock is having a great month with double-digit gains, a momentum it has carried for the past three months with gains now in three digits, over 130%. The company is gaining renewed visibility following its presentation last week at the 2025 Cell & Gene Therapy International Conference in Boston. It is reported that the company highlighted progress in lipid nanoparticle (LNP) formulation, a critical enabler for delivering next-generation gene-editing therapies. Despite the latest scientific update, I believe that Prime still faces some significant risks. These include modest revenue, persistent losses, heavy reliance on external funding and execution uncertainty until 2027. My other concerns include investor exposure to cash burn and intense competition in gene editing. I choose to apply caution and assign a Hold rating to PRME stock for now....

Read the full article on Seeking Alpha

For further details see: